Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 10/01/2022)

1st line
ImmunoSABR (Academic)
Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer.

PDC-LUNG-101 (PDC*line)
Safety, Immunogenicity and Preliminary Clinical Activity Study of  PDC*Lung01 Cancer Vaccine in NSCLC.
(cohort B1 open)

ZEAL (GSK)
Placebo-controlled Study Comparing Niraparib Plus Pembolizumab Versus Placebo Plus Pembrolizumab as Maintance Therapy in Participants with Advanced/Metastatic Non-small Cell Lung Cancer.

2th line 
Carmen (Sanofi) (after chemo- and immunotherapy)
SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients.

ARTEMIDE (AstraZeneca)
A Study to Assess the Safety and Efficacy of AZD2936 in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).

ImmunoSABR (Academic)
Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer.

3th line
ARTEMIDE (AstraZeneca)
A Study to Assess the Safety and Efficacy of AZD2936 in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).

ImmunoSABR (Academic)
Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer.